Here are six things to know from the report:
1. The company’s total revenue for the second quarter is expected to hit $33.5 million, down 6 percent for the same period last year.
2. Orthobiologics revenue is projected to increase 1 percent to $17 million.
3. The spinal fusion hardware revenue will be down 13 percent to $16.5 million for the second quarter.
4. Full-year revenue is expected to reach $133 million to $139 million, flat or down 4 percent compared with the same period last year. This is unchanged from the previous guidance Integra LifeSciences projected.
5. SeaSpine became an independent company July 1 and is investing in innovation and growth initiatives. The orthobiologics platform is the leading platform.
6. President and CEO Keith Valentine reported the company has a robust research and development pipeline that includes spinal fusion hardware products recently launched. The company expects to launch additional products in the second half of this year.
More articles on orthopedic devices:
Smith & Nephew to build US headquarters in Fort Worth
Nevro announces positive results from SENZA system study
Is Stryker next for a big transaction?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
